• Asian Pacific Journal of Cancer Prevention
• /
• v.15 no.17
• /
• pp.7303-7307
• /
• 2014

Objective: To explore the clinical efficacy of gemcitabine concomitant with nedaplatin and drug resistance in the treatment of non-small cell lung cancer (NSCLC) and associated molecular predicators. Materials and Methods: A total of 68 patients diagnosed with NSCLC by histology served as the study objects and were randomly divided into an observation group treated with gemcitabine concomitant with nedaplatin and a control group with cisplatin concomitant with gemcitabine, 34 cases for each group. Short-term and long-term efficacies, adverse responses as well as the expression of nucleotide excision repair cross complementing 1 (ERCC1), ribonucleotide reductase subunit M1 (RRM1) and lung resistance-related protein (LRP) in NSCLC tissues in both groups were assessed. Results: The short-term objective response rate (ORR) and disease control rate (DCR) were 35.3% (12/34) and 76.5% (26/34) in the observation group and 38.2% (13/34) and 85.3% (29/34) in the control group, respectively, the differences not being statistically significant. The time to progression (TTP) in both groups were 1~12 months, while the median TTP was 135 d and 144 d, respectively. Though the survival was slightly higher in the control group, there were no significant differences in TTP and survival time. The rates of decreased hemoglobin, vomiting and nausea as well as renal toxicity were evidently lower in the observation group, while other adverse responses demonstrated no significant difference. The positive expression rates of ERCC1, RRM1 and LRP were 47.1% (16/34), 61.8% (21/34) and 64.7% (22/34) in the observation group, respectively. Compared with negative ERCC1 expression, ORR had decreasing trend and the overall survival time (OS) decreased significantly in patients with positive ERCC1 expression, which were markedly decreased by the positive expressions of RRM1 and LRP. Conclusions: Gemcitabine concomitant with nedaplatin has significant effects in the treatment of NSCLC, with an adverse response rate obviously lower than for cisplatin concomitant with gemcitabine, suggesting that wider use in the clinic is warranted. Additionally, the positive expressions of ERCC1, RRM1 and LRP may increase patient drug resistance, so they can be applied as the chemotherapeutic predicators to guide individualized therapy of NSCLC patients.

• Korean Journal of Adult Nursing
• /
• v.23 no.4
• /
• pp.340-350
• /
• 2011

Purpose: This study was designed to analyze the characteristics and effect size of published intervention studies related to nausea & vomiting among cancer patients. Methods: A total of 1,083 studies were retrieved. From these studies, 20 studies met the inclusion criteria with a total of 698 participants. Two authors independently extracted data from the selected studies and assessed the methodological quality. The data were analyzed by the RevMan 5.0 program of Cochrane library. Results: The twenty studies utilized various non-pharmacological interventions: Nine studies on acupuncture (45%), Five studies utilized massage (25%), Two studies used oral cryotherapy (10%) and Four studies used other therapies. In the twenty studies the effect size of the intervention studies reported a higher effect sizes for massage (d=-1.62) and acupuncture (d=-0.89). Conclusion: This study suggests that non-drug therapy can reduce the levels of nausea and vomiting intensity. Massage and acupuncture interventions studies were more numerous and this may account for the higher effect rate.

• Korean Journal of Acupuncture
• /
• v.29 no.4
• /
• pp.501-518
• /
• 2012

Objectives : To research trends of studies on treatments of lumbar herniated intervertebral disc in Korean medicine. Methods : We searched papers using Korean Traditional Knowledge Portal, OASIS, KISS. We used "low back pain", "radiculopathy", "lumbar herniated intervertebral disc" as keyword. Limitations were as follows; Domestic studies, published from 2000 to 2011, mentioning the treatments of lumbar herniated intervertebral disc in Korean medicine. This study researched and classified the papers according to the fields of the treatment and methods of study. Results : The results were obtained as below ; 1. The number of papers published in 2000 was only three, but steadily increased to 15 in 2010 and the total number of papers was 93. 2. When categorized according to the fields of treatment, 93 researches are classified as acupuncture, moxibustion, Chuna therapy, drug, various physical therapies and collaborative Oriental-Western medicine therapy. 3. When categorized according to the methods of study, 70 researches were the simple case report and non-RCT(non-randomized controlled trial) were 11 and RCT(randomized controlled trials) has been reported in 11 researches. 4. General assessment tools were VAS, ODI before, however these days, Physical examination(ROM, SLRT, etc.), Radiologic tests(MRI, X-ray), DITI etc. are used more in order to evaluate objective therapeutic effects. Conclusions : These results indicate that researches on lumbar herniated intervertebral disc in Korean medicine have been investigated by various method and steadily increasing.

• Asian Pacific Journal of Cancer Prevention
• /
• v.16 no.8
• /
• pp.3351-3354
• /
• 2015

Background: Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in the pediatric age group. All patients with RMS regardless of their initial stage or group receive combination chemotherapy as 'standard therapy' consisting of vincristine, actinomycin-D and cyclophosphamide. Actinomycin-D was not readily available in Turkey at one time. Carboplatin was used instead in order to prevent delays in treatment. The aim of this report is to present the results of patients with rhabdomyosarcoma receiving carboplatin or actinomycin-D therapy. Materials and Methods: Twenty four patients with rhabdomyosarcoma treated between December 2000 and June 2011 were included in this retrospective study. The patients were treated according to International Rhabdomyosarcoma Study Group guidelines. Eleven patients were treated with actinomycin-D and 13 with carboplatin ($250mg/m^2/dose$ for 2 days). The two groups were then compared in terms of 2- and 5-year overall survival (OS) and hematological and non-hematological toxicities. Results: Age, sex, stage and the mean duration of follow-up were similar in both groups (p>0.05). Two- and five-year OS levels were 68.2% in the carboplatin group and 78.0% and 40.0%, respectively, in the actinomycin-D group. There was no statistical difference in the number of febrile episodes (p=0.86) and no other hematological and non-hematological adverse effects were recorded in both groups. Conclusions: The findings show that carboplatin can be used as an alternative drug in the primary treatment of rhabdomyosarcoma in the event that actinomycin-D is unavailable or not tolerated.

• Toxicological Research
• /
• v.35 no.1
• /
• pp.9-12
• /
• 2019

One of the major challenges in methadone maintenance therapy (MMT) for drug dependence is the physiological side effects on endocrine hormones. Because of the key role of the thyroid gland in the normal functioning of the human body and brain, this study examined the effect of MMT on thyroid function. Thyroid hormones (T3, T4, and thyroid-stimulating hormone (TSH)) were evaluated in normal and user treated with MMT who were referred to the Province Clinical & Pathology Center of Urmia, Iran. The study was conducted for three months using the Case Series method. A total of 270 samples were collected, 215 were from individuals who were not treated, whereas 55 were from men treated with methadone. Average levels of T3 and T4 in non-treated sample of men are $1.34{\pm}0.02ng/mL$ and $90.96{\pm}1.38ng/mL$ while the corresponding values for patients treated with methadone are $1.39{\pm}0.04ng/mL$ for T3 and $94.57{\pm}2.72ng/mL$ for T4. Mean TSH levels of the non-treated group and the methadone consuming group were $1.75{\pm}0.08{\mu}IU/mL$ and $3.17{\pm}0.45{\mu}IU/mL$, respectively. These results indicate that although men treated with methadone had higher levels of T3, T4, and TSH than normal individuals, only the difference in TSH level was significant. The importance of this difference among individuals on methadone maintenance programs should be investigated in larger samples over long periods of time. Additionally, the effects of methadone treatment on women should be examined.

• Tuberculosis and Respiratory Diseases
• /
• v.67 no.2
• /
• pp.121-126
• /
• 2009

Background: Pemetrexed has been prescribed newly as a second line chemotherapy in advanced non-small cell lung carcinoma (NSCLC). The aim of study was to determine the efficacy and toxicity of pemetrexed in advanced NSCLC. Methods: Patients with histologically or cytologically confirmed NSCLC were evaluated from June 2006 to December 2008. The patients had relapsed or progressed after prior chemotherapy treatment. They were treated with intravenous pemetrexed $500mg/m^2$ for 10 min on Day 1 of each 21-day cycle. Results: A total of 89 patients were eligible for analysis. The response rate and disease control rate were 11% and 66%. Non-squamous cell carcinoma histology was significantly associated with a superior response rate (p=0.035) and disease control rate (p=0.009) than squamous cell carcinoma histology. The median survival time was 13 months and the median progression free survival time was 2.3 months. The median survival time of patients with ECOG PS 0~1 was 13.2 months, whereas median survival time was 11.6 months for patients with PS 2 (p=0.002). The median progression free survival time of patients with PS 0~1 were 3.8 months, but 2.1 months for patients with PS 2 (p=0.016). The median progression free survival time of smokers with non-squamous cell carcinoma was 3.4 months, which was significant (p=0.014). Grade 3~4 neutropenia were seen in 7.9% patients. Conclusion: Pemetrexed has efficacy in patients who had prior chemotherapy with advanced NSCLC and less hematologic toxicity.

• Proceedings of the Korean Society of Medical Physics Conference
• /
• 2004.11a
• /
• pp.153-156
• /
• 2004

Korea Food and Drug Administration(KFDA) has peformed the calibration of therapy level dosimeters for Co-60 radiation since 1979. The reference standard ionization chamber has been calibrated at BIPM in France. The uncertainty on the KFDA calibration coefficients is 0.9 %(k=2) for air kerma and absorbed dose to water. Since 1999 a national quality audit program for ensuring dosimetry accuracy in Korea radiotherapy centers has been performed by the KFDA. The uncertainty associated with the determination of the absorbed dose to water from the TLD readings for high energy x-ray is 1.6 %(k=1). The correction factors for energy, non-linearity dose response, and TLD holder are used in the dose determination. Agreement between the user stated dose and KFDA measured dose within ${\pm}$ 5 % is considered acceptable. KFDA TLD postal dose quality audit program was peformed for 71 beam qualities of 53 domestic radiotherapy centers in 2003. The results for quality assurance showed that 63 out of 71 beam qualifies (89 %) satisfied the acceptance limit. The second audit was carried out for the centers outside the limit and ail of them have been corrected.

• Korean Journal of Clinical Laboratory Science
• /
• v.55 no.4
• /
• pp.298-305
• /
• 2023

Burkitt's lymphoma is a distinct subtype of non-Hodgkin's lymphoma originating from B-cells that is notorious for its aggressive growth and association with immune system impairments, potentially resulting in rapid and fatal outcomes if not addressed promptly. Optimizing the use of Food and Drug Administration-approved medications, such as combining known safe drugs, can lead to time and cost savings. This method holds promise in accelerating the progress of novel treatments, ultimately facilitating swifter access for patients. This study explores the potential of a dual-targeted therapeutic strategy, combining the bruton tyrosine kinase-targeting drug Ibrutinib and the epidermal growth factor receptor/human epidermal growth factor receptor-2-targeting drug Lapatinib. Ramos and Daudi cell lines, well-established models of Burkitt's lymphoma, were used to examine the impact of this combination therapy. The combination of Ibrutinib and Lapatinib inhibited cell proliferation more than using each drug individually. A combination treatment induced apoptosis and caused cell cycle arrest at the S and G2/M phases. This approach is multifaceted in its benefits. It enhances the efficiency of the drug development timeline and maximizes the utility of currently available resources, ensuring a more streamlined and resource-effective research process.

• 지역과문화
• /
• v.7 no.4
• /
• pp.49-68
• /
• 2020

The study of complementary medicine for the mental illness of modern people has been made up of academic fields. Psychotherapy, art therapy, literary therapy and dance therapy are among them, but these non-integrated studies are extremely limited to apply to reality. Collaboration with the medical community seeking supplementary measures after drug treatment is also a problem, and it is even more difficult to institutionalize them in a policy way. In response, the study suggested a shift to a space-oriented treatment paradigm by studying the value of space that most treatment programs value. Based on the theory of integrated literature therapy developed in Germany and introduced into Korea, the Tetra system was applied to one of Korea's cultural heritages. And I presented a sample of how to program the characteristics of the old house space. Kwon Seong-baek old house in Andong was considered a representative space and analyzed. As a similar case, we looked at the Healian Sun Village, the Knife Village in Germany, and the Temple Stay of Bongeunsa Temple to find out the actual conditions of space utilization. Accordingly, space treatment programs such as walking, writing poems, reading poems, and writing letters were presented by analyzing old houses with a Tetra system. This is significant as the first study to incorporate spatialization and placeability into the program.

• Korean Journal of Biological Psychiatry
• /
• v.24 no.4
• /
• pp.167-174
• /
• 2017

Based on advances in biotechnology and neuroscience, neuromodulation is poised to gain clinical importance as a treatment modality for psychiatric disorders. In addition to old-established electroconvulsive therapy (ECT), clinicians are expected to understand newer forms of neurostimulation, such as deep brain stimulation (DBS), vagus nerve stimulation (VNS), repetitive transcranial magnetic stimulation (rTMS), transcranial direct current stimulation (tDCS) and transcranial alternating current stimulation (tACS). Given the growing interest in non-invasive neuromodulation technologies, clinicians may seek sufficient information about neuromodulation to inform their clinical practice. A growing literature suggests that applications of non-invasive neuromodulation have evidence particularly for indications where treatments are currently insufficient, such as drug-resistant depression. However, positive neuromodulation studies require replication, and the precise interactions among stimulation, antidepressant medication, and psychotherapy are unknown. Further studies of long-term safety and the impact on the developing brain are needed. Non-invasive neuromodulatory devices could enable more individualized treatment. However, do-it-yourself (DIY) stimulation kits require a better understanding of the effects of more frequent patterns of stimulation and raise concerns about clinical supervision, regulation, and reimbursement. Wide spread enthusiasm for therapeutic potential of neuromodulation in clinical practice settings should be mitigated by the fact that there are still research gaps and challenges associated with non-invasive neuromodulatory devices.